ClinicalTrials.gg
CompletedNCT01885156Updated Apr 15, 2015

Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris

A Phase 3 interventional study of Naftin 1% Cream and Placebo Cream in Tinea Cruris and Jock Itch, sponsored by Merz North America, Inc.. Completed at 5 sites in 3 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2015-04-15.

Sponsored by Merz North America, Inc. (part of Merz Pharma) · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Study summary

To see how well Naftin 1% cream works when applied once daily to the affected area. The results will be compared to those using a placebo cream, which is a cream with no active ingredient. Safety will also be measured.

02

Conditions studied

  • Tinea Cruris
  • Jock Itch
03

In context

Lead sponsor

Merz North America, Inc. is the lead sponsor of 53 studies on the registry; 2 are open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 19 (95%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Review and sign statement of and HIPAA authorization.
  • Males or non-pregnant females ≥ 12 years of age to 17 years, 11 months, of any race or sex. Females of must have a negative urine pregnancy test.
  • The parent/legal guardian must complete the informed consent process AND the subject must complete the assent process and sign the appropriate form (if age appropriate).
  • Presence of tinea cruris characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling, and mild pruritus) based on signs and symptoms.
  • KOH positive baseline skin scrapings obtained from the site most severely affected or a representative site of the overall severity.
  • Subjects must be in good health and free from any disease that might interfere with the study evaluations.
  • Subject must be able to understand the requirements of the study and willing to comply with the study requirements.

Exclusion criteria

Exclusion Criteria:

  • A life threatening condition (ex. deficiency syndrome, cancer, unstable angina, or myocardial infarction) within the last 6 months.
  • Subjects with abnormal findings - physical or laboratory - that are considered by the investigator to be and indicative of conditions that might complicate interpretation of study results.- Severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection.
  • Subjects with a known to study medications or their components.
  • Subjects who have a recent history or who are currently known to abuse alcohol or drugs.
  • Uncontrolled diabetes mellitus.
  • Hemodialysis or chronic ambulatory peritoneal dialysis therapy.
  • Current diagnosis of immunocompromising conditions.
  • Atopic or contact dermatitis.
  • Severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection.
  • Female subject who is pregnant or lactating, who is not using or does not agree to use an acceptable form of during the study, or who intends to become pregnant during the study (females who are surgically sterilized for at least 2 years are not considered to be of ).
  • Subjects using the following medications:

    • Topical anti-fungal therapy, powders or topical applied within 14 days prior to randomization. Terbinafine, butenafine, and naftifine (topical) within 30 days prior to randomization.
    • Oral anti-fungal therapies within 3 months of randomization (8 months for oral terbinafine).
    • Systemic antibiotic or corticosteroid treatment within 30 days of randomization.
    • Any other significant treatments, except hormonal contraception and multivitamin, at the discretion of the investigator that would interfere with study treatment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Placebo comparator
    Placebo Cream

    Topically applied once daily

    Drug: Placebo Cream

  • Experimental
    Naftin 1% Cream

    Topically applied once daily

    Drug: Naftin 1% Cream

Interventions

  • Topically applied once a day

  • DrugPlacebo Cream

    Topically applied once a day

06

What researchers measure

Primary outcomes

  1. Safety of Naftin® 1% Cream, applied once daily for 4 weeks, compared to vehicle for treatment of subjects with KOH positive symptomatic tinea cruris in adolescent subjects (aged 12 years to 17 years, 11 months).

    - Summarization of AEs (local and systemic)

    Time frame: Week 6

Secondary outcomes

  1. Efficacy of Naftin® 1% Cream, applied once daily for 4 weeks, compared to vehicle for treatment of subjects with KOH and culture positive symptomatic tinea cruris in adolescent subjects (aged 12 years to 17 years, 11 months).

    Complete Cure based on: -Negative mycology results; absence (Grade 0) of erythema, scaling, and pruritis Other efficacy variables assessed at Week 2, Week 4, and Week 6: * Effective treatment * Mycological cure * Clinical Success * Clinical Cure * Investigator Global Assessment * Subject Satisfaction Assessment

    Time frame: Week 6

07

Study locations

5 sites
  • Merz Investigational Site # 501001
    Belize City, Belize
  • Merz Investigational Site # 501002
    Belize City, Belize
  • Merz Investigative Site # 180002
    San Cristobal, Dominican Republic
  • Merz Investigative Site # 180001
    Santo Domingo, Dominican Republic
  • Merz Investigative Site # 504001
    San Pedro Sula, Honduras
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2013
First posted
Jun 24, 2013
Start
Aug 2013
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results delay requested
Mar 26, 2015
Last update
Apr 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01885156
Responsible party
Sponsor
First posted
Jun 24, 2013
Start date
Aug 2013
Primary completion
Nov 2013
Completion
Nov 2013
Last update
Apr 15, 2015

Study contacts

Stefan Plaum, MD
study director · Merz North America, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naftifine

Start the discussion